Penserra Capital Management LLC Editas Medicine, Inc. Transaction History

Penserra Capital Management LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	BUY	$6.92 - $9.31 $1,640 - $2,206	237 Added 1.96%	12,348 $96,000
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $3,873 - $6,985	-609 Reduced 4.79%	12,111 $99,000
Q1 2023 Apr 24, 2023	BUY	$7.03 - $11.53 $3,022 - $4,957	430 Added 3.5%	12,720 $92,000
Q4 2022 Feb 13, 2023	SELL	$8.32 - $13.21 $31,690 - $50,316	-3,809 Reduced 23.66%	12,290 $109,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $91,528 - $146,174	7,527 Added 87.81%	16,099 $197,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $7,992 - $17,080	800 Added 10.29%	8,572 $101,000
Q1 2022 May 13, 2022	BUY	$14.08 - $27.63 $109,429 - $214,740	7,772 New	7,772 $147,000
Q4 2021 Feb 15, 2022	SELL	$26.55 - $40.57 $41,418 - $63,289	-1,560 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $589 - $1,094	15 Added 0.97%	1,560 $64,000
Q2 2021 Aug 12, 2021	BUY	$31.29 - $56.64 $782 - $1,416	25 Added 1.64%	1,545 $87,000
Q1 2021 May 13, 2021	BUY	$39.71 - $90.58 $3,573 - $8,152	90 Added 6.29%	1,520 $63,000
Q4 2020 Feb 12, 2021	BUY	$27.07 - $84.35 $24,308 - $75,746	898 Added 168.8%	1,430 $100,000
Q3 2020 Nov 13, 2020	BUY	$28.06 - $37.16 $14,927 - $19,769	532 New	532 $14,000

240

56.5M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $85.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Penserra Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Penserra Capital Management LLC with notifications on news.